Is NCT06713616 recruiting in Milford, CT?

Yes, NCT06713616 is currently recruiting participants at its Milford, CT location. This treatment-resistant depression clinical trial is actively enrolling qualified participants.

How do I join the treatment-resistant depression clinical trial in Milford?

To join this clinical trial in Milford, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Milford clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Treatment-Resistant Depression Clinical Trial in Milford, CT

About This Treatment-Resistant Depression Study in Milford

The purpose of this study is to compare the relative effectiveness, acceptability, and side effects of ketamine delivered through an IV (a drip into the arm) which is not currently FDA approved for use in the treatment of treatment-resistant depression (TRD) and Esketamine (Spravato®), taken as a nasal spray which has received FDA approval for use in the treatment of treatment-resistant depression (TRD) in the treatment of patients with treatment-resistant depression (TRD). The study will look a

Sponsor: Yale University

Who Can Participate

Inclusion Criteria

Provision of signed and dated informed consent form

Stated willingness to comply with all study procedures and availability for the duration of the study

Adults ages 18 or older

Diagnosis of major depressive disorder that is refractory to two or more antidepressant trials

Moderate or severe depression based on an initial MADRS score ≥ 25

Judged appropriate for ketamine or esketamine by clinician, independent of potential study participation

A female participant must be: a. Not of childbearing potential\*, OR b. Of childbearing potential and practicing a highly effective method of contraception (failure rate of \<1% per year when used consistently and correctly) and agrees to remain on a highly effective method while receiving study intervention and until 1 week after last dose - the end of relevant systemic exposure. The investigator will evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of drug. Acceptable methods of contraception are: i. combined (estrogen and progestogen containing) hormonal or progestogen-only hormonal contraception associated with inhibition of ovulation (oral, transdermal, or intravaginal) ii. intrauterine device (IUD) iii. intrauterine hormone-releasing system (IUS) iv. bilateral tubal occlusion/ligation v. male partner with a bilateral vasectomy with documented aspermia or a bilateral orchiectomy vi. male or female condom with spermicide, diaphragm, or sponge with spermicide (Note: Use of condom as the sole method of contraception is not considered to be a highly effective method of contraception).

A female participant must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study \

We will consider women to be of childbearing potential if they are within 2 years of menopause (within 3 years since last menstrual period) and have not had a hysterectomy, bilateral oophorectomy, or other definitive surgical intervention.

Exclusion Criteria

Diagnosis of bipolar disorder or psychotic disorder (i.e., schizophrenia, schizoaffective disorder)

Other psychiatric comorbidities are permitted so long as depression is the predominant diagnosis

Active or recent (within 12 months) substance use disorder (other than nicotine)

Pregnant or lactating women

Intracerebral hemorrhage or aneurysmal vascular disease

Hypersensitivity to ketamine, esketamine or any of the excipients

Known family history of ketamine use disorder

Prior known ketamine use disorder as well as subjects for whom study participations will result in more than 8 lifetime exposures to ketamine (e.g., prior exposure to ketamine, prior recreational use with ketamine). Prior esketamine exposure is also exclusionary.

Uncontrolled hypertension, as demonstrated by a blood pressure of greater than 145 / 90 at screening visit. (Pre-treatment blood pressure will be permitted to be 150 / 95 to allow for "whitecoat" hypertension on treatment visits 1-8.)

Known cardiovascular and cerebrovascular conditions that are associated with an increased risk related to ketamine or esketamine administration (including space-occupying CNS lesions). This includes those prospective participants who undergo EKG and are shown to have an abnormality that would put them at increased risk related to treatment.

Known condition for which an acute rise in blood pressure would pose a serious risk.

Arteriovenous malformation

Positive urine toxicology at screening visit, except for substances that are prescribed (i.e., benzodiazepines, stimulants). Given the extended length of time between exposure and negative toxicology screen, a positive screen for THC will not be exclusionary unless the pattern of use and clinical evaluation are indicative of cannabis use disorder. Cannabis used within 24 hours of dosing is exclusionary.

Positive alcohol breathalyzer at screening or clinical signs of intoxication

The patient is unable to arrange for someone to drive them home after each treatment session; patients who are unwilling to refrain from driving and operating machinery on treatment days until the next day following sleep will be excluded.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Milford?

Yes, this clinical trial (NCT06713616) has an active research site in Milford, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Treatment-Resistant Depression Treatment Options in Milford, CT

If you're searching for treatment-resistant depression treatment options in Milford, CT, this clinical trial (NCT06713616) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Milford research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced treatment-resistant depression specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all treatment-resistant depression clinical trials near you to find additional studies recruiting in your area.

Treatment-Resistant Depression Clinical Trial in Milford, CT

Expert Care in Milford

IRB Approved

No-Cost Care

Apply for This Milford Location

Why Participate?

Simple Process